The Operation principles of Antibody-drug Conjugates

Bella Smith

Abstract

The complexity of ADCs consisting of payloads, and conjugated antibodies and ADC linkers creates difficulties in developing new pharmacokinetic research methods, understanding the in vivo processes of drugs, and the relationship between therapeutic effects and safety, and thus new organisms. Analytic method research and development are increasingly valued. Recent literature on ADC characterization, biodistribution, metabolism, and elimination can be found in the importance of research and development of antibody drugs, particularly ADC drugs. Biological analysis of ADCs is challenging compared to small molecule drugs and protein therapies because ADCs have a complex molecular structure that has the molecular characteristics of combining small molecule drugs with protein therapies. The ADC runs from the serum or plasma to the site of action or to the target cell. Under the action of the enzyme, the antibody-linker-active drug is cleaved to release the drug and produce a therapeutic effect. For this novel drug action method, the bioanalytical method must take into account the antibody-linker-active drug, and it needs to be specially designed for this complex ADC delivery system to provide more and more complete pharmacokinetic information, but cannot be achieved by traditional biological analysis methods.

Citation: Bella Smith The Operation principles of Antibody-drug Conjugates. **protocols.io** dx.doi.org/10.17504/protocols.io.rcpd2vn
Published: 28 Jun 2018

Document